Your browser doesn't support javascript.
loading
Moderate Psoriasis: A Proposed Definition. / Psoriasis moderada. Propuesta de definición.
Llamas-Velasco, M; de la Cueva, P; Notario, J; Martínez-Pilar, L; Martorell, A; Moreno-Ramírez, D.
Affiliation
  • Llamas-Velasco M; Departamento Dermatología, Hospital Universitario la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, España. Electronic address: mar.llamasvelasco@gmail.com.
  • de la Cueva P; Departamento Dermatología, Hospital Universitario Infanta Leonor, Madrid, España.
  • Notario J; Departamento Dermatología, Hospital de Bellvitge, Barcelona, España.
  • Martínez-Pilar L; Departamento Dermatología, Hospital Regional Universitario Carlos Haya, Málaga, España.
  • Martorell A; Departamento Dermatología, Hospital de Manises, Valencia, España.
  • Moreno-Ramírez D; Departamento Dermatología, Hospital Universitario Virgen de la Macarena, Sevilla, España.
Actas Dermosifiliogr ; 108(10): 911-917, 2017 Dec.
Article in En, Es | MEDLINE | ID: mdl-28823420
ABSTRACT

INTRODUCTION:

The Psoriasis Area Severity Index (PASI) is the most widely used scale for assessing the severity of psoriasis and for therapeutic decision making. On the basis of the PASI score, patients have been stratified into 2 groups mild disease and moderate-to-severe disease.

OBJECTIVE:

To draft a proposal for the definition and characterization of moderate psoriasis based on PASI and Dermatology Life Quality Index (DLQI) scores. MATERIAL AND

METHODS:

A group of 6 dermatologists with experience in the treatment of psoriasis undertook a critical review of the literature and a discussion of cases to draft a proposal.

RESULTS:

In order of priority, PASI, DLQI, and body surface area (BSA) are the parameters to be used in daily practice to classify psoriasis as mild, moderate, or severe. Severity should be assessed on the basis of a combined evaluation and interpretation of the PASI and DLQI. And 3, PASI and DLQI should carry equal weight in the determination of disease severity. On this basis, psoriasis severity was defined using the following criteria mild, PASI<7 and DLQI<7; moderate, PASI=7-15 and DLQI=5-15 (classified as severe when difficult-to-treat sites are affected or when there is a significant psychosocial impact); severe, PASI >15, independently of the DLQI score.

CONCLUSIONS:

A more precise classification of psoriasis according to disease severity will improve the risk-benefit assessment essential to therapeutic decision making in these patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Severity of Illness Index Type of study: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En / Es Journal: Actas Dermosifiliogr Year: 2017 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Severity of Illness Index Type of study: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En / Es Journal: Actas Dermosifiliogr Year: 2017 Document type: Article